Ovoca Bio plc (OVB.L)

GBp 1.6

(3.23%)

Market Cap (In GBp)

1.3 Million

Revenue (In GBp)

-

Net Income (In GBp)

-4.7 Million

Avg. Volume

397.47 Thousand

Currency
GBp
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.451-1.98
PE
-
EPS
-
Beta Value
0.935
ISIN
IE00B4XVDC01
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Timothy Rand McCutcheon
Employee Count
-
Website
https://ovocabio.com
Ipo Date
2000-01-04
Details
Ovoca Bio plc, a clinical-stage biopharmaceutical company, engages in the development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing BP-101, a medicinal treatment for premenopausal women with hypoactive sexual desire disorder, which is in phase II clinical study in Australia and New Zealand, and in phase III clinical trials in Russia. It also engages in mineral exploration, as well as provides support services. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was incorporated in 1985 and is based in Dublin, Ireland.